Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications — CPB 0886 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0886 on March 4, 2026, classifying optical coherence tomography (OCT) and microelastography across a wide range of surgical and diagnostic indications as experimental, investigational, or unproven. If your team bills CPT 0351T, 0352T, 0353T, 0354T, 0470T, 0471T, or elastography codes 76981–76983 for Aetna members, expect denials.

Aetna's CPB 0886 OCT coverage policy now draws a hard line: no intraoperative OCT or microelastography use case covered under this bulletin gets a pass. That list runs from breast-conserving surgery margin assessment to OCT-guided solid tumor resection to quantitative photoacoustic elastography for tumor detection. The effective date is March 4, 2026. If you haven't audited your charge capture and surgical case billing against this policy, do it now.

---

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications
Policy Code	CPB 0886
Change Type	Modified
Effective Date	March 4, 2026
Impact Level	High
Specialties Affected	Surgical oncology, ophthalmology, general surgery, breast surgery, ENT/head and neck surgery, colorectal surgery, urology, neurosurgery
Key Action	Audit any claims billing 0351T–0354T, 0470T–0471T, or 76981–76983 for Aetna members and flag for denial risk before submitting

---

Aetna OCT Coverage Policy and Medical Necessity Requirements 2026

The Aetna OCT coverage policy under CPB 0886 is unambiguous. Every intraoperative OCT and microelastography application listed in this bulletin is experimental, investigational, or unproven. Aetna has not established medical necessity for any of them.

This matters for your authorization workflow. Because none of these applications meet Aetna's medical necessity standard, pursuing prior authorization is unlikely to be productive — consult your payer contract for specifics on how Aetna handles experimental designations. The policy doesn't describe conditions under which coverage would apply. It simply doesn't cover these procedures.

Optical coherence tomography billing for Aetna members needs to be screened against CPB 0886 at the point of surgical scheduling, not after the claim is submitted. Facilities and physician groups that perform OCT-guided surgery — particularly breast, oncology, and ophthalmology — carry the highest denial exposure here.

The reimbursement risk is real. These are Category III CPT codes (0351T–0354T, 0470T–0471T), which already face coverage gaps across many payers. Under this Aetna coverage policy, they're explicitly non-covered.

---

Aetna OCT and Microelastography Exclusions and Non-Covered Indications

This section is the core of CPB 0886 Aetna system policy. Aetna groups the non-covered indications into several categories. Each one is worth understanding separately, because the clinical scope is wide.

Intraoperative microscope-integrated OCT is not covered for microvascular surgery guidance or ophthalmic surgery. This applies broadly — any surgical team using a microscope-integrated OCT system during these procedures is billing outside Aetna's covered services.

Intraoperative OCT and microelastography covers the largest group of denied indications. The policy specifically calls out:

Intraoperative polarization-sensitive OCT adds five more non-covered uses:

OCT combined with convolutional neural networks — the AI-assisted imaging applications — are also non-covered. This includes OCT/CNN differentiation of colorectal tissue, intrahepatic cholangiocarcinoma vs. liver parenchyma, and colorectal liver metastases from liver parenchyma. This is a forward-looking exclusion. Aetna is specifically naming AI-enhanced OCT as unproven.

Quantitative microelastography for residual cancer detection during breast-conserving surgery is not covered. Neither is quantitative photoacoustic elastography for tumor detection. Your billing team should consult the policy directly to confirm applicable codes for each indication.

Ultrasonic microelastography for ocular disease diagnosis — including keratoconus and post-refractive keratectasia — and treatment monitoring including cross-linking surgery is not covered.

Finally, OCT for margin definition of basal cell carcinoma before Mohs surgery is not covered. If your Mohs billing team uses OCT to define margins before CPT codes in the 17311–17315 range, the OCT component (CPT 0470T or 0471T) will be denied under this policy. Review CPB 0383 (Mohs Micrographic Surgery) alongside this one.

---

Coverage Indications at a Glance

---

Aetna OCT Billing Guidelines and Action Items 2026

The effective date of March 4, 2026 is already active. These steps are not future-tense.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for OCT and Microelastography Under CPB 0886

Not Covered / Experimental CPT Codes — Intraoperative OCT and Microelastography

Related Procedure CPT Codes Listed in Policy

These codes represent the underlying surgical procedures with which non-covered OCT/microelastography use is associated. They are listed in CPB 0886 as related codes, not as independently denied codes.

Key ICD-10-CM Diagnosis Code Ranges

The policy lists 576 ICD-10-CM codes. These represent the diagnosis codes associated with the conditions for which OCT and microelastography are being used — and denied. Key ranges include:

The full ICD-10 list spans nearly every solid tumor diagnosis category. If you're treating a patient with a malignant neoplasm diagnosis and OCT is used intraoperatively, the diagnosis code will not save the claim. The exclusion is technique-based, not diagnosis-based.

---